A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...
The blockbuster drugs Ozempic and Wegovy may help people cut back on drinking, new research published Wednesday in JAMA ...
The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...
周三,诺和诺德公布了三季度业绩,减肥药Wegovy当季销售额超出预期。这一消息让投资者们松了一口气,因为其竞争对手礼来上周报告的减肥药销量令人失望。受此影响,美股诺和诺德盘前大涨5%。今年以来,由于减肥药火爆,诺和诺德股价一路走高,并于6月25日触及 ...
据港交所文件,11月13日,杭州九源基因工程股份有限公司通过港交所上市聆讯。据文件披露,于2024年6月18日,诺和诺德用于治疗超重及肥胖症的司美格鲁肽产品Wegovy(诺和盈)在中国获得批准,这可能会对公司的JY29-2(吉可亲)造成竞争。由于预期的竞争,公司计划就JY29-2(吉可亲)与Wegovy进行对比研究,作为其评估JY29 ...
A healthy high protein prepared meal including chicken, carrots, fruits and greens. Taking Wegovy (semaglutide) can be a ...
Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.
【ITBEAR】诺和诺德三季度财报亮相,减肥药Wegovy销售额超预期,引领业绩增长。 丹麦制药巨头诺和诺德近日发布2024年第三季度财报,显示公司营收与净利润均实现增长,其中明星减肥药Wegovy的销售额更是超出市场预期,成为推动业绩增长的重要力量 ...
丹麦制药公司诺和诺德公司报告称,其肥胖药物Wegovy在第三季度的销售强劲,超过了分析师的预期。销售额达到173亿丹麦克朗(约合24.9亿美元),比上一季度增长48%,高于预期的159亿克朗。
生产“减肥神药”Wegovy的丹麦药厂诺和诺德 (Novo Nordisk)第三季盈利273.01亿丹麦克朗 ...